TRT vs Natural Boosters: Which Actually Raises Testosterone?

What "natural testosterone boosters" actually do

Most over-the-counter testosterone boosters do not raise testosterone to clinically meaningful levels. A 2021 systematic review in the World Journal of Men's Health examined 50 top-selling supplements and found that only 24.8% contained ingredients with any peer-reviewed evidence, and the observed testosterone increases rarely exceeded 20 to 50 ng/dL above placebo [1]. That is a small shift when the normal male reference range spans 300, 1 to 000 ng/dL.

The better-studied compounds tell a more honest story. Ashwagandha (KSM-66 to 600 mg/day for 8 weeks) raised serum testosterone by a mean of 15% versus placebo in a double-blind trial (N=57) [2]. Vitamin D3 supplementation (3 to 332 IU/day for 12 months) increased total testosterone from 10.7 nmol/L to 13.4 nmol/L in 54 men with deficiency, a statistically significant but modest change [3]. Zinc repletion helps only in verified deficiency; supplementing replete men adds nothing measurable [4].

Natural supplements may be appropriate for men with total testosterone between 350 to 450 ng/dL who have borderline symptoms and no pituitary or testicular pathology. Below 300 ng/dL on two morning draws, the Endocrine Society's 2018 Clinical Practice Guideline states: "We recommend testosterone therapy for symptomatic men with classic androgen deficiency syndromes" [5]. Supplements are not a substitute at that level.

How TRT works and what it consistently delivers

TRT replaces the testosterone your testes are not making. Injecting testosterone cypionate 100 mg weekly, for example, raises total serum testosterone into the 500 to 800 ng/dL range for most men within four to six weeks [6]. The hypothalamic-pituitary-gonadal (HPG) axis reads the exogenous hormone and suppresses LH and FSH, which is why testicular volume decreases by roughly 25% over 6 to 12 months of standard TRT [7].

The clinical benefits are well-documented. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies (N=788 men, mean age 72, mean baseline T 234 ng/dL), showed that one year of transdermal testosterone gel increased sexual desire scores significantly, improved walking distance by 44 meters more than placebo, and improved bone mineral density at the lumbar spine [8]. Mood and depressive symptoms also improved at 12 months in men with baseline PHQ-9 scores above 5 [9].

The tradeoff is HPG suppression. Intratesticular testosterone, which drives spermatogenesis, drops precipitously on exogenous therapy. Men who want to maintain fertility should not start standard TRT without first discussing concurrent hCG or switching to a fertility-preserving alternative [10].

Enclomiphene vs TRT: the fertility-first option

Enclomiphene citrate is the trans-isomer of clomiphene. It blocks estrogen receptors in the hypothalamus, causing the pituitary to secrete more LH and FSH, which then stimulates the testes to produce testosterone endogenously. The testes keep working. Sperm counts can rise rather than fall.

A Phase 3 randomized controlled trial (N=124) published in Fertility and Sterility compared enclomiphene 12.5 mg and 25 mg daily against transdermal testosterone 1% gel for 3 months in men with secondary hypogonadism [11]. Enclomiphene 25 mg raised mean total testosterone from 230 ng/dL to 431 ng/dL. The gel arm raised testosterone similarly to 460 ng/dL. The difference: sperm concentration fell 26% in the gel group and rose 17% in the enclomiphene group by month three. That single data point is the reason clinicians consider enclomiphene first for men under 45 with ongoing or future fertility goals.

Enclomiphene is not FDA-approved as of early 2025. It is prescribed off-label or through compounding pharmacies. Typical dosing is 12.5 to 25 mg orally once daily. Response should be assessed at 6 to 8 weeks with a repeat morning total testosterone draw [12].

The HealthRX clinical team uses a three-gate decision framework before recommending enclomiphene over TRT: (1) confirmed secondary hypogonadism with low or normal LH/FSH rather than primary testicular failure, (2) total testosterone above 150 ng/dL (severely suppressed testes may not respond adequately to stimulation), and (3) no active estrogen-receptor-positive malignancy. Men who clear all three gates are candidates for enclomiphene as first-line therapy.

Clomid (clomiphene citrate) vs TRT

Clomiphene citrate (brand name Clomid) contains both the trans-isomer (enclomiphene, which stimulates testosterone) and the cis-isomer (zuclomiphene, which has a longer half-life and may contribute estrogenic side effects including visual disturbances and mood changes). The Endocrine Society notes that clomiphene is used off-label for male hypogonadism despite no FDA approval for that indication [5].

A randomized trial by Kim et al. (N=90) published in the Journal of Urology found that clomiphene 25 mg every other day raised mean total testosterone from 249 ng/dL to 463 ng/dL at 3 months, with sperm concentration maintained or improved in all men [13]. The FDA has not approved clomiphene for male hypogonadism. Prescribers cite it under the off-label authority recognized in the FDA's guidance on unapproved uses of approved drugs [14].

The practical difference between clomiphene and enclomiphene comes down to isomer purity. Enclomiphene contains only the active stimulatory isomer, so the same testosterone lift typically occurs with fewer estrogenic side effects. For men who tolerate clomiphene without visual or mood side effects, cost can be a reason to stay on it. Generic clomiphene runs roughly $15, $30 per month versus $60, $120 for compounded enclomiphene.

Cypionate vs enanthate: the injection choice

Testosterone cypionate and testosterone enanthate deliver the same active molecule. The difference is the ester chain attached to delay absorption from the injection depot. Cypionate carries an 8-carbon ester; enanthate carries a 7-carbon ester. Cypionate has an elimination half-life of approximately 8 days; enanthate is approximately 4.5 days [15].

In clinical practice, both are injected weekly or twice weekly and produce essentially indistinguishable serum testosterone curves when dosed equivalently. A pharmacokinetic crossover study (N=14) in Clinical Endocrinology showed that 200 mg cypionate and 200 mg enanthate given every two weeks produced peak testosterone levels (Cmax) of 1 to 197 ng/dL and 1 to 166 ng/dL respectively, with overlapping AUC values and no statistically significant difference between them [16].

Cypionate is manufactured almost exclusively in the United States. Enanthate is the more common formulation in Europe and is available generically worldwide. Availability and cost, not pharmacology, typically determine which one a clinician prescribes. If your clinic stocks one, there is no clinical reason to switch to the other.

Injection-site reactions may differ slightly because cypionate is dissolved in cottonseed oil and enanthate in sesame or castor oil. Men with sesame or castor-oil sensitivity should use cypionate [17]. Standard subcutaneous injection volumes of 0.5 mL or less reduce injection-site discomfort regardless of ester.

Cypionate vs testosterone gel: injection vs absorption

Testosterone gel (brand names: AndroGel, Testim, Vogelxo) delivers testosterone transdermally. The FDA-approved dose range for AndroGel 1.62% is 20.25 to 81 mg/day applied to the shoulders and upper arms [18]. Serum levels peak 2 to 8 hours after application and return toward trough within 24 hours, giving a flatter, more physiological daily curve than weekly injections.

The TTrials used transdermal gel as the active arm and achieved mean testosterone of 453 ng/dL versus 234 ng/dL at baseline in 788 participants [8]. That is a clinically meaningful rise. The limitation is absorption variability. Inter-individual coefficient of variation for steady-state serum testosterone on gel exceeds 30% in pharmacokinetic studies [19]. Two men using the same daily dose can have troughs of 280 ng/dL and 620 ng/dL respectively. Cypionate injections, particularly at consistent once-weekly or twice-weekly intervals, show lower intra-individual variability because bioavailability after IM or subcutaneous injection approaches 100%.

A second concern with gel is transfer to female or pediatric household members via skin contact. The FDA issued a black box warning for AndroGel in 2009 citing cases of virilization in children exposed through secondary transfer [18]. Hands and application sites must be washed and covered before contact.

Gel suits men who dislike injections, have no needle-sharing concerns, and live alone or can reliably cover application sites. Injections suit men who want tighter control over trough-to-peak ratios and more predictable lab values. Neither formulation is superior in terms of long-term clinical outcomes when titrated to equivalent serum levels [20].

Direct comparison: TRT vs enclomiphene vs Clomid vs supplements

A plain comparison across the four categories clarifies the decision:

Magnitude of testosterone increase. TRT produces the largest and most reliable rise, typically 200 to 500 ng/dL above baseline regardless of testicular function. Enclomiphene and Clomid depend on the testes responding to LH/FSH stimulation; men with primary testicular failure (high LH, low T) will not respond adequately. Supplements produce modest gains only in men with specific deficiencies.

Fertility. TRT suppresses spermatogenesis. Studies using quantitative semen analysis show sperm concentrations below 1 million/mL in 40 to 50% of men after 6 months of standard injectable TRT [7]. Enclomiphene preserves or improves sperm output. Clomiphene does the same. Supplements have no meaningful impact on spermatogenesis in either direction [21].

Endogenous axis. TRT shuts down the HPG axis. Enclomiphene and Clomid work through the axis. Recovery after TRT cessation takes a median of 3 to 6 months but can take over 24 months in some men, particularly those who used high doses or long durations [22].

Symptom relief speed. Libido and energy improvements appear within 3 to 6 weeks on TRT [8]. Enclomiphene and Clomid may take 6 to 12 weeks to raise testosterone high enough to relieve symptoms because the pituitary-to-testis signaling chain introduces lag. Supplements show the slowest timeline; ashwagandha studies show mood and energy effects at 8 weeks but testosterone changes at 8 to 12 weeks [2].

Regulatory status. Injectable and topical testosterone products are FDA-approved for male hypogonadism. Clomiphene is FDA-approved for female ovulatory dysfunction only, prescribed off-label in men. Enclomiphene citrate failed to receive FDA approval in 2013 for reasons related to long-term safety data and remains investigational in the US. Supplements are regulated as dietary supplements under DSHEA 1994, meaning no pre-market efficacy or safety review is required [23].

Who should consider each option

Men with primary hypogonadism (elevated LH, FSH; damaged testes) will not respond to enclomiphene or Clomid and need exogenous testosterone. The Endocrine Society defines hypogonadism requiring treatment as total testosterone persistently below 300 ng/dL on two morning draws plus at least one symptom from the classic triad: decreased libido, erectile dysfunction, or reduced energy [5].

Men with secondary hypogonadism (low or normal LH, FSH; intact testicular function) and fertility goals are the ideal candidates for enclomiphene or Clomid. A semen analysis and LH/FSH draw before starting any therapy costs under $150 at most labs and provides the data needed to choose correctly.

Men in the 300 to 450 ng/dL range with mild symptoms and no structural pathology may reasonably trial ashwagandha 600 mg/day or vitamin D3 3,000, 4 to 000 IU/day for 12 weeks and reassess [2, 3]. Below 300 ng/dL on two separate draws, supplementation alone is unlikely to close the gap.

Monitoring and safety considerations

All testosterone therapies require periodic laboratory monitoring. The Endocrine Society recommends checking hematocrit at 3 to 6 months and then annually on TRT, given the erythrocytosis risk [5]. Testosterone stimulates erythropoiesis; hematocrit above 54% signals a need to reduce dose, increase injection frequency, or donate blood [24]. Prostate-specific antigen (PSA) should be checked at baseline, 3 to 6 months, and annually in men over 40 [5].

Enclomiphene and Clomid require monitoring of total testosterone, LH, FSH, and estradiol at 6 to 8 weeks. Because these agents increase LH drive to the testes, they also increase aromatase activity and estradiol production. Some men need a low-dose aromatase inhibitor (anastrozole 0.25 to 0.5 mg twice weekly) if estradiol rises above 40, 50 pg/mL with symptoms of gynecomastia or water retention [25].

Supplements have a lower monitoring burden but are not risk-free. High-dose zinc (above 40 mg/day) impairs copper absorption and may cause neurological symptoms with prolonged use [4]. Ashwagandha contains withanolides that have shown hepatotoxic effects in rare case reports; men with liver disease should avoid it [26].

Cypionate injection protocol: practical details

Standard starting doses for testosterone cypionate range from 100 to 200 mg per week, split into once or twice-weekly subcutaneous or intramuscular injections [6]. Twice-weekly dosing (e.g., 50 mg every 3.5 days) reduces peak-to-trough swing from roughly 400 ng/dL on once-weekly to under 200 ng/dL, which most men find produces fewer mood fluctuations and less post-injection fatigue [27].

Subcutaneous injection (25-gauge, 5/8-inch needle, abdomen or lateral thigh, 0.5 mL maximum per site) has been shown in a prospective study of 32 men to produce bioavailable testosterone levels equivalent to intramuscular injection with less injection-site discomfort and no difference in serum estradiol or hematocrit at 12 weeks [28]. Needle phobia is cited by 15 to 20% of men as a reason to prefer gel or oral options [19].